

Akceptējami ir formalīnā fiksētu audu parafīna bloki (FFPE), tostarp stikliņi ar griezumiem


Perifērisko asiņu paraugs, kaulu smadzeņu aspirāts vai FFPE audu paraugi, ko var izmantot ar ≥20% audzēja šūnu saturu

IHC - imūnchistoķīmija (immunohistochemistry). PD-L1 - programmētās šūnu bojāejas ligands 1 (programmed death-ligand 1).
References
- FoundationOne®CDx Technical Specifications, 2018. Pieejams: www.rochefoundationmedicine.com/f1cdxtech (piekļuve 2018. gada oktobrī).
- FoundationOne®Liquid Technical Specifications, 2018. Pieejams: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (pieeja 2018. gada oktobrī).
- FoundationOne®Heme Technical Specifications, 2017. Pieejams: www.foundationmedicine.com/genomic-testing/foundation-one-heme (pieeja 2018. gada oktobrī).
- FoundationOne®CDx Specimen Instructions, 2018. Pieejams: www.rochefoundationmedicine.com/specimen (piekļuve 2018. gada oktobrī).
- FoundationOne®Liquid Specimen instructions 2018. Pieejams: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (piekļuve 2018. gada oktobrī).
- FoundationOne®Heme Specimen Instructions, 2017. Pieejams: www.foundationmedicine.com/genomic-testing/foundation-one-heme (pieeja 2018. gada oktobrī).
- Kamzi S. Presented at ESMO Immuno Oncology Congress 2017; Geneva, Switzerland: Poster no. 35P.
- Rizvi H et al. J Clin Oncol 2018; 36: 633–641.
- Hellmann MD et al. Cancer Cell 2018; 33: 843–852.e4.